317 related articles for article (PubMed ID: 17693902)
1. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
[TBL] [Abstract][Full Text] [Related]
2. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
Hemelaar M; Rosing J; Kenemans P; Thomassen MC; Braat DD; van der Mooren MJ
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1660-6. PubMed ID: 16645152
[TBL] [Abstract][Full Text] [Related]
3. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
4. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
6. Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
Hemelaar M; Kenemans P; de Bie L; van de Weijer PH; van der Mooren MJ
Fertil Steril; 2006 Apr; 85(4):979-88. PubMed ID: 16580384
[TBL] [Abstract][Full Text] [Related]
7. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
Junge W; El-Samalouti V; Gerlinger C; Schaefers M
Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
[TBL] [Abstract][Full Text] [Related]
8. Effect of pulsed estrogen therapy on hemostatic markers in comparison with oral estrogen regimen in postmenopausal women.
Basurto L; Saucedo R; Zárate A; Martínez C; Gaminio E; Reyes E; Hernandez M
Gynecol Obstet Invest; 2006; 61(2):61-4. PubMed ID: 16192735
[TBL] [Abstract][Full Text] [Related]
9. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.
Hemelaar M; Kenemans P; Schalkwijk CG; Braat DD; van der Mooren MJ
Hum Reprod; 2006 Jun; 21(6):1635-42. PubMed ID: 16501036
[TBL] [Abstract][Full Text] [Related]
10. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
[TBL] [Abstract][Full Text] [Related]
11. [Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens].
Winkler UH; Krämer R; Kwee B; Schindler AE
Zentralbl Gynakol; 1995; 117(10):540-8. PubMed ID: 7491837
[TBL] [Abstract][Full Text] [Related]
12. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen.
Rozenberg S; Pornel B; Koninckx PR; Palacios S; Christiansen C
Hum Reprod; 2009 Jul; 24(7):1739-47. PubMed ID: 19351658
[TBL] [Abstract][Full Text] [Related]
13. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
14. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis.
Teede HJ; McGrath BP; Smolich JJ; Malan E; Kotsopoulos D; Liang YL; Peverill RE
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1404-9. PubMed ID: 10807761
[TBL] [Abstract][Full Text] [Related]
15. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
[TBL] [Abstract][Full Text] [Related]
16. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
[TBL] [Abstract][Full Text] [Related]
17. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause.
Perrone G; Capri O; Galoppi P; Brunelli R; Bevilacqua E; Ceci F; Ciarla MV; Strom R
Gynecol Obstet Invest; 2009; 68(1):33-9. PubMed ID: 19349712
[TBL] [Abstract][Full Text] [Related]
18. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
Vogelvang TE; Mijatovic V; Kenemans P; Emeis JJ; Heijst JA; van der Mooren MJ
Am J Obstet Gynecol; 2005 Oct; 193(4):1384-94. PubMed ID: 16202731
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
[TBL] [Abstract][Full Text] [Related]
20. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
Brynhildsen J; Hammar M
Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
